ANI PHARMACEUTICALS, INC
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $176.8M | $128.6M | $76.3M | $56.0M | $30.1M | $20.4M | $435.2K | $2.5M |
| Cost of Revenue | $79.0M | $48.8M | $12.7M | $11.5M | $10.0M | $9.2M | — | — |
| Gross Profit | $97.8M | $79.8M | $63.6M | $44.5M | $20.1M | $11.2M | — | — |
| Gross Margin | 55.3% | 62.1% | 83.4% | 79.5% | 66.8% | 55.0% | — | — |
| Operating Expenses | ||||||||
| Research & Development | $9.1M | $2.9M | $2.9M | $2.7M | $1.7M | $1.2M | $44.2M | $39.7M |
| SG&A Expense | $31.6M | $27.8M | $21.2M | $17.9M | $16.4M | $9.5M | $7.0M | $5.9M |
| Operating Income | $28.3M | $20.1M | $32.7M | $20.0M | $898.0K | $-42.0K | $-50.9M | $-45.5M |
| Operating Margin | 16.0% | 15.6% | 42.8% | 35.7% | 3.0% | -0.2% | -11,703.0% | -1,839.3% |
| Interest Expense | $11.3M | $11.3M | $11.1M | $811.0K | $467.0K | $1.3M | $681.6K | $688.1K |
| Pretax Income | $16.3M | $8.7M | $21.7M | $19.4M | $126.0K | $-1.6M | $-51.6M | $-46.2M |
| Income Tax Expense | $17.4M | $4.7M | $6.4M | $-9.4M | $20.0K | $-36.0K | — | — |
| Net Income | $-1.1M | $3.9M | $15.4M | $28.7M | $301.0K | $-1.5M | $-51.6M | $-46.2M |
| Net Margin | -0.6% | 3.1% | 20.1% | 51.4% | 1.0% | -7.4% | -11,859.7% | -1,867.1% |
| EPS (Basic) | $-0.09 | $0.34 | $1.34 | $2.61 | $-0.46 | $-0.64 | $-1.58 | $-2.11 |
| EPS (Diluted) | $-0.09 | $0.34 | $1.32 | $2.59 | $-0.46 | $-0.64 | $-1.58 | $-2.11 |
| Shares Outstanding (Basic) | 11.5M | 11.4M | 11.4M | 10.9M | 10.1M | 43.5M | 32.8M | 22.0M |
| Shares Outstanding (Diluted) | 11.5M | 11.6M | 11.6M | 11.1M | 10.1M | 43.5M | 32.8M | 22.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |